StockMacro
Menu

Tenax Therapeutics

$1.25 -90% in 6 monthsMarket cap $56.9M

TENX on XNAS, Health Care, Tenax Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 84% in 12 months while insiders bought $6.4M and short interest is 31 times a year earlier.

  • BadNet loss of $65.8M over 12 months; cash on hand $113.7M

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Industry
Pharmaceutical preparations (Health Care)
Employees
16
Website
tenaxthera.com
Listed
Nasdaq, US
Last results
5 Nov 2026
Next results
expected around 9 Mar 2027 (an estimate: a year ago it reported on 10 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $0, net loss $16.7M.
Quarter to 31 Dec 2021: revenue –, net income -$61.7MQuarter to 31 Mar 2022: revenue –, net income -$2.7MQuarter to 30 Jun 2022: revenue –, net income $2.9MQuarter to 30 Sep 2022: revenue –, net income $2.9MQuarter to 31 Dec 2022: revenue –, net income -$19.5MQuarter to 31 Mar 2023: revenue –, net income $1.4MQuarter to 30 Jun 2023: revenue –, net income -$1.1MQuarter to 30 Sep 2023: revenue –, net income $2.0MQuarter to 31 Mar 2024: revenue –, net income $3.8MQuarter to 30 Jun 2024: revenue –, net income $3.6MQuarter to 30 Sep 2024: revenue –, net income $4.0MQuarter to 31 Mar 2025: revenue $0, net income -$10.4MQuarter to 31 Mar 2025: revenue $0, net income -$10.4MQuarter to 30 Jun 2025: revenue $0, net income -$10.8MQuarter to 30 Jun 2025: revenue $0, net income -$10.8MQuarter to 30 Sep 2025: revenue $0, net income -$15.8MQuarter to 30 Sep 2025: revenue $0, net income -$15.8MQuarter to 31 Dec 2025: revenue $0, net income -$15.5MQuarter to 31 Dec 2025: revenue $0, net income -$15.5MQuarter to 31 Mar 2026: revenue $0, net income -$15.7MQuarter to 31 Mar 2026: revenue $0, net income -$15.7MQuarter to 30 Jun 2026: revenue $0, net income -$17.8MQuarter to 30 Jun 2026: revenue $0, net income -$17.8MQuarter to 30 Sep 2026: revenue $0, net income -$16.7MQuarter to 30 Sep 2026: revenue $0, net income -$16.7M
31 Dec 2021RevenueNet incomeNet losstallest bar $61.7M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$0-$16.7M
30 Jun 2026$0-$17.8M
31 Mar 2026$0-$15.7M
31 Dec 2025$0-$15.5M
30 Sep 2025$0-$15.8M
30 Jun 2025$0-$10.8M
31 Mar 2025$0-$10.4M
30 Sep 2024–$4.0M
30 Jun 2024–$3.6M
31 Mar 2024–$3.8M
30 Sep 2023–$2.0M
30 Jun 2023–-$1.1M
31 Mar 2023–$1.4M
31 Dec 2022–-$19.5M
30 Sep 2022–$2.9M
30 Jun 2022–$2.9M
31 Mar 2022–-$2.7M
31 Dec 2021–-$61.7M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$65.8M -$43.3M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$1.39 -$0.73
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -64.2% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $113.7M $99.4M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$113.7M (net cash) –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $2.39
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.52 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Tenax TherapeuticsTENX (this company) $56.9Mloss–––
iBioIBIO $56.4Mloss52.4+115%–
Azora TherapeuticsAZR $55.0Mloss–––
Rani TherapeuticsRANI $59.0Mloss9.0+449%-493%
Boundless BioBOLD $54.8Mloss–––
Xilio TherapeuticsXLO $53.4Mloss0.97+73%-20.9%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$6.4M

bought $6.4M, sold $0

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-5.4%

105 13F filers vs 111

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

70%

31.9M shares held by 13F filers (30 Sep 2026) of 45.5M outstanding (31 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

13%

5.8M shares sold short (30 Oct 2026) of 45.5M outstanding (31 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

3.2

5.8M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-20%

7.2M shares sold short in the report before, 5.8M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

33%

33% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 38%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

26

26 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

8.7×

26 articles in the last 7 days; its usual week has 3.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Short interest 9.3M, 31× a year earlier
  • Insider buying $4.8M, 3 insiders

Price $1.25 on 20 Nov 2026, -84% over 12 months (12-month range $1.25 to $18.32)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $6.5M in the last 12 months (the 12 months before: $93K).
Revenue per quarter. Revenue $0 in the latest quarter.
Capital spending per quarter. Capital spending $2K in the latest quarter.
Institutional holders (13F filers). 105 13F filers reported holding it in the latest 13F quarter, +218% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 2026Sharp changeShort interest spike: short interest spike, 5.8M vs usual 760K (2026-10-30); 7.6x the same period a year earlier
27 Oct 2026Sharp changeShort interest spike: short interest spike, 7.2M vs usual 756K (2026-10-15); 9.6x the same period a year earlier
13 Oct 2026Sharp changeShort interest spike: short interest spike, 7.2M vs usual 743K (2026-09-30); 13.0x the same period a year earlier
29 Sep 2026Sharp changeShort interest spike: short interest spike, 5.5M vs usual 666K (2026-09-15); 20.0x the same period a year earlier
16 Sep 2026Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 5 filing(s) in 30 days, value_usd total 4.8M)
15 Sep 2026Sharp changeShort interest spike: short interest spike, 9.3M vs usual 577K (2026-08-31); 31.2x the same period a year earlier
1 Sep 2026Sharp changeShort interest spike: short interest spike, 5.5M vs usual 542K (2026-08-14); 16.7x the same period a year earlier
18 Aug 2026Sharp changeShort interest spike: short interest spike, 2.6M vs usual 433K (2026-07-31); 7.6x the same period a year earlier
29 Jun 20268-K and other filingsDirector or officer change
19 May 2026Sharp changeMany funds opening a new position: many funds opening a new position, 30 vs usual 4.50 (2026-03-31); 7.5x the same period a year earlier
22 Apr 20268-K and other filingsDirector or officer change
22 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Jan 20268-K and other filingsDirector or officer change
9 Jan 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Dec 2025Sharp changeShort interest spike: short interest spike, 600K vs usual 331K (2025-11-28); 4.6x the same period a year earlier
6 Dec 2025Sharp changeClustered insider buying: clustered insider buying (4 independent filers, 4 filing(s) in 30 days, value_usd total 139K)
2 Dec 2025Sharp changeShort interest spike: short interest spike, 758K vs usual 319K (2025-11-14); 6.3x the same period a year earlier
18 Nov 2025Sharp changeShort interest spike: short interest spike, 762K vs usual 311K (2025-10-31); 7.2x the same period a year earlier
28 Oct 2025Sharp changeShort interest spike: short interest spike, 754K vs usual 310K (2025-10-15); 35.9x the same period a year earlier
4 Dec 20248-K and other filingsDirector or officer change
30 Oct 20248-K and other filingsDirector or officer change
30 Oct 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
23 Aug 20248-K and other filingsPrivate placement of securities (Form D)
13 Jun 20248-K and other filingsDirector or officer change
13 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Feb 20248-K and other filingsRegistered new securities for sale (S-1)
1 Feb 20248-K and other filingsRegistered new securities for sale (S-1)
12 Jan 20248-K and other filingsDirector or officer change
12 Jan 20248-K and other filingsDelisting notice or listing transfer
12 Jan 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Dec 20238-K and other filingsRegistered new securities for sale (S-1)
28 Nov 2023Sharp changeShort interest spike: short interest spike, 3.0M vs usual 179K (2023-11-15); 7.6x the same period a year earlier
29 Sep 20238-K and other filingsDelisting notice or listing transfer
30 Mar 20238-K and other filingsDelisting notice or listing transfer
28 Mar 2023Sharp changeShort interest spike: short interest spike, 2.2M vs usual 84K (2023-03-15); 65.5x the same period a year earlier
10 Feb 20238-K and other filingsA major agreement ended
31 Jan 20238-K and other filingsRegistered new securities for sale (S-1)
23 Jan 20238-K and other filingsRegistered new securities for sale (S-1)
17 Jan 2023Sharp changeShort interest spike: short interest spike, 663K vs usual 51K (2022-12-30); 4.2x the same period a year earlier
3 Jan 2023Sharp changeShort interest spike: short interest spike, 593K vs usual 51K (2022-12-15); 3.8x the same period a year earlier
13 Dec 2022Sharp changeShort interest spike: short interest spike, 1.4M vs usual 51K (2022-11-30); 7.4x the same period a year earlier
18 Aug 20228-K and other filingsDelisting notice or listing transfer
16 Jun 20228-K and other filingsDirector or officer change
10 Jun 20228-K and other filingsDirector or officer change
10 Jun 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Jun 20228-K and other filingsPrivate placement of securities (Form D)
18 Feb 20228-K and other filingsDelisting notice or listing transfer
31 Jan 20228-K and other filingsDirector or officer change
31 Jan 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Aug 2024: $0 published
Month from 1 Nov 2025: $93K published
Month from 1 Dec 2025: $96K published
Month from 1 Aug 2026: $1.8M published
Month from 1 Sep 2026: $3.1M published
Month from 1 Oct 2026: $1.5M published
Revenue per quarter
Quarter ended 31 Mar 2025: $0; public on 15 May 2025
Quarter ended 30 Jun 2025: $0; public on 14 Aug 2025
Quarter ended 30 Sep 2025: $0; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $0; public on 11 Mar 2026
Quarter ended 31 Mar 2026: $0; public on 13 May 2026
Quarter ended 30 Jun 2026: $0; public on 1 Aug 2026
Quarter ended 30 Sep 2026: $0; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2021: $0; public on 17 May 2022
Quarter ended 31 Dec 2021: $2K, -51% on a year earlier; public on 30 Mar 2022
Quarter ended 30 Jun 2022: $0, -100% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $0, -100% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Mar 2023: $1K; public on 16 May 2023
Quarter ended 30 Jun 2023: $2K; public on 15 Aug 2023
Institutional holders (13F filers)
31 Dec 2021 report: 28; public on 14 Feb 2022
31 Mar 2022 report: 25; public on 16 May 2022
30 Jun 2022 report: 25; public on 15 Aug 2022
30 Sep 2022 report: 27; public on 14 Nov 2022
31 Dec 2022 report: 18; public on 14 Feb 2023
31 Mar 2023 report: 13; public on 15 May 2023
30 Jun 2023 report: 13; public on 14 Aug 2023
30 Sep 2023 report: 13; public on 14 Nov 2023
31 Dec 2023 report: 16; public on 14 Feb 2024
31 Mar 2024 report: 8; public on 15 May 2024
30 Jun 2024 report: 11; public on 14 Aug 2024
30 Sep 2024 report: 19; public on 14 Nov 2024
31 Dec 2024 report: 21; public on 14 Feb 2025
31 Mar 2025 report: 23; public on 15 May 2025
30 Jun 2025 report: 24; public on 14 Aug 2025
30 Sep 2025 report: 33; public on 14 Nov 2025
31 Dec 2025 report: 45; public on 17 Feb 2026
31 Mar 2026 report: 78; public on 15 May 2026
30 Jun 2026 report: 111; public on 14 Aug 2026
30 Sep 2026 report: 105; public on 16 Nov 2026

What is unusual now

  • Made public in the last 90 days: it had 9.3M shares sold short in the 31 Aug 2026 report, 31× the same report last year; it also had 5.5M shares sold short in the 14 Aug 2026 report, 17× the same report last year. 7 sharp changes in all. Two or more unrelated kinds of activity agreed on 16 Sep 2026.
  • Short interest spike: had 9.3M shares sold short in the 31 Aug 2026 report, 31× the same report last year Public on 11 Sep 2026.
  • Insider net buying (open market): Insiders bought a net $6.5M in the last 12 months (the 12 months before: $93K).
  • Revenue per quarter: Revenue $0 in the latest quarter.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 25 insider trades

Last 90 days: no sales; 6 purchases, $4.6M. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
21 Oct 2026ADAR1 Capital Management, LLC and 1 other10% ownerBuy922,849$1.59$1.5MForm 4
17 Sep 2026Declan DooganDirectorBuy53,000$1.92$102KForm 4
15 Sep 2026Christopher Thomas GiordanoCEOBuy10,850$1.85$20KForm 4
15 Sep 2026Thomas R Staab IIChief Financial OfficerBuy5,675$1.94$11KForm 4
8 Sep 2026ADAR1 Capital Management, LLC and 1 other10% ownerBuy900,000$1.78$1.6MForm 4
2 Sep 2026Daniel Schneeberger and 1 other10% ownerBuy770,333$1.79$1.4MForm 4
24 Aug 2026Daniel Schneeberger and 1 other10% ownerBuy1,025,867$1.77$1.8MForm 4
10 Dec 2025Stuart RichChief Medical OfficerBuy5,000$10.16$51KForm 4

105 institutions reported shares at the end of Q3 2026, 70% of the shares outstanding; 30 opened a position, 37 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
ADAR1 Capital Management, LLC6.5M14.3%$12.3M+6.3M30 times as many
BlackRock, Inc.2.8M6.16%$5.3M+1.1M+62%
Vivo Capital, LLC2.5M5.49%$4.7MNo change
Sphera Funds Management Ltd.2.3M5.09%$4.4M+2.2M19 times as many
Marshall Wace, LLP1.8M3.91%$3.4M+1.2M+204%
Millennium Management LLC1.4M2.99%$2.6M+486K+56%
AQR Capital Management LLC1.3M2.75%$2.4MNew+1.3M
Vanguard Capital Management LLC1.1M2.49%$2.1M-15K-1.3%
Morgan Stanley943K2.07%$1.8M+511K+118%
Geode Capital Management, LLC865K1.90%$1.6M+225K+35%

Federal contracts

All 1 federal contracts

No new award in 12 months; the latest was signed 1 Mar 2011. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
1 Mar 2011Department of DefenseDepartment of the Army$1.9MPRECLINICAL AND CLINICAL STUDIES OF EXYCOTE, A NOVEL TBI THERAPEUTIC FOR COMBAT CASUALTIESGrantUSAspending

Company events

All 61 company events

In 12 months: 3 director or officer changes, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
30 Jun 2026Signed a major agreement8-K
29 Jun 2026Director or officer change8-K
22 Apr 2026Director or officer change8-K
9 Jan 2026Director or officer change8-K
9 Sep 2025Signed a major agreement8-K
6 Mar 2025Signed a major agreementSame filing: sold shares privately8-K
4 Dec 2024Director or officer change8-K
30 Oct 2024Director or officer changeSame filing: shareholder vote results8-K

The 5 newest of 167 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

16 Sep 2026confirmed

Confirmed across sources Insiders and Short interest and volume

Tenax Therapeutics (TENX): had 9.3M shares sold short in the 31 Aug 2026 report, 31× the same report last year, while it had 3 insiders buy $4.8M of its shares on the open market within 30 days (5 filings). Two unrelated kinds of activity within 91 days.

  • Short interest and volume: Short interest spike, became public on 12 Aug 2026
  • Short interest and volume: Short interest spike, became public on 26 Aug 2026
  • Short interest and volume: Short interest spike, became public on 11 Sep 2026
  • Insiders: Clustered insider buying, became public on 16 Sep 2026
  • Short interest and volume: Short interest spike, became public on 25 Sep 2026
  • Short interest and volume: Short interest spike, became public on 10 Oct 2026
  • Short interest and volume: Short interest spike, became public on 27 Oct 2026
  • Short interest and volume: Short interest spike, became public on 11 Nov 2026
2025-08-29: 298K2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K2025-12-15: 531K2025-12-31: 93K2026-01-15: 196K2026-01-30: 120K2026-02-13: 124K2026-02-27: 120K2026-03-13: 153K2026-03-31: 173K2026-04-15: 194K2026-04-30: 731K2026-05-15: 776K2026-05-29: 792K2026-06-15: 768K2026-06-30: 1.8M2026-07-15: 2.0M2026-07-31: 2.6M2026-08-14: 5.5M2026-08-31: 9.3M
The 31 Aug 2026 report against the 24 reports before it. this reportearliernormal: 577K
See the evidence (8 changes)

Short interest and volume: Short interest spike became public on 12 Aug 2026

Tenax Therapeutics had 2.6M shares sold short in the 31 Jul 2026 report, 7.6× the same report last year.

This period
2.6M (the 31 Jul 2026 report)
Normal report (median of 24 earlier)
433K
Typical spread (median absolute deviation)
303K
How far from its usual level
+4.7
Same report last year
335K
History used
3,136 days
2025-07-31: 335K2025-08-15: 327K2025-08-29: 298K2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K2025-12-15: 531K2025-12-31: 93K2026-01-15: 196K2026-01-30: 120K2026-02-13: 124K2026-02-27: 120K2026-03-13: 153K2026-03-31: 173K2026-04-15: 194K2026-04-30: 731K2026-05-15: 776K2026-05-29: 792K2026-06-15: 768K2026-06-30: 1.8M2026-07-15: 2.0M2026-07-31: 2.6M
the 31 Jul 2026 report24 earlier reportsnormal: 433K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Aug 2026

Tenax Therapeutics had 5.5M shares sold short in the 14 Aug 2026 report, 17× the same report last year.

This period
5.5M (the 14 Aug 2026 report)
Normal report (median of 24 earlier)
542K
Typical spread (median absolute deviation)
258K
How far from its usual level
+12.9
Same report last year
327K
History used
3,150 days
2025-08-15: 327K2025-08-29: 298K2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K2025-12-15: 531K2025-12-31: 93K2026-01-15: 196K2026-01-30: 120K2026-02-13: 124K2026-02-27: 120K2026-03-13: 153K2026-03-31: 173K2026-04-15: 194K2026-04-30: 731K2026-05-15: 776K2026-05-29: 792K2026-06-15: 768K2026-06-30: 1.8M2026-07-15: 2.0M2026-07-31: 2.6M2026-08-14: 5.5M
the 14 Aug 2026 report24 earlier reportsnormal: 542K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Sep 2026

Tenax Therapeutics had 9.3M shares sold short in the 31 Aug 2026 report, 31× the same report last year.

This period
9.3M (the 31 Aug 2026 report)
Normal report (median of 24 earlier)
577K
Typical spread (median absolute deviation)
341K
How far from its usual level
+17.2
Same report last year
298K
History used
3,167 days
2025-08-29: 298K2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K2025-12-15: 531K2025-12-31: 93K2026-01-15: 196K2026-01-30: 120K2026-02-13: 124K2026-02-27: 120K2026-03-13: 153K2026-03-31: 173K2026-04-15: 194K2026-04-30: 731K2026-05-15: 776K2026-05-29: 792K2026-06-15: 768K2026-06-30: 1.8M2026-07-15: 2.0M2026-07-31: 2.6M2026-08-14: 5.5M2026-08-31: 9.3M
the 31 Aug 2026 report24 earlier reportsnormal: 577K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Insiders: Clustered insider buying became public on 16 Sep 2026

Tenax Therapeutics had 3 insiders buy $4.8M of its shares on the open market within 30 days (5 filings).

Independent buyers
3
Purchase filings (Form 4, code P)
5
Total bought
$4.8M
Window
17 Aug 2026 to 16 Sep 2026
  • Schneeberger Daniel (ten percent owner) and 1 other(s) bought 1,025,867 shares of TENX ($1.8M)dated 24 Aug 2026, public 25 Aug 2026
  • Schneeberger Daniel (ten percent owner) and 1 other(s) bought 770,333 shares of TENX ($1.4M)dated 2 Sep 2026, public 3 Sep 2026
  • ADAR1 Capital Management, LLC (ten percent owner) and 1 other(s) bought 900,000 shares of TENX ($1.6M)dated 8 Sep 2026, public 9 Sep 2026
  • Giordano Christopher Thomas (CEO) bought 10,850 shares of TENX ($20,107)dated 15 Sep 2026, public 16 Sep 2026
  • STAAB THOMAS R II (Chief Financial Officer) bought 5,675 shares of TENX ($11,010)dated 15 Sep 2026, public 16 Sep 2026

Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

Short interest and volume: Short interest spike became public on 25 Sep 2026

Tenax Therapeutics had 5.5M shares sold short in the 15 Sep 2026 report, 20× the same report last year.

This period
5.5M (the 15 Sep 2026 report)
Normal report (median of 24 earlier)
666K
Typical spread (median absolute deviation)
470K
How far from its usual level
+6.9
Same report last year
275K
History used
3,182 days
2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K2025-12-15: 531K2025-12-31: 93K2026-01-15: 196K2026-01-30: 120K2026-02-13: 124K2026-02-27: 120K2026-03-13: 153K2026-03-31: 173K2026-04-15: 194K2026-04-30: 731K2026-05-15: 776K2026-05-29: 792K2026-06-15: 768K2026-06-30: 1.8M2026-07-15: 2.0M2026-07-31: 2.6M2026-08-14: 5.5M2026-08-31: 9.3M2026-09-15: 5.5M
the 15 Sep 2026 report24 earlier reportsnormal: 666K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Oct 2026

Tenax Therapeutics had 7.2M shares sold short in the 30 Sep 2026 report, 13× the same report last year.

This period
7.2M (the 30 Sep 2026 report)
Normal report (median of 24 earlier)
743K
Typical spread (median absolute deviation)
559K
How far from its usual level
+7.8
Same report last year
554K
History used
3,197 days
2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K2025-12-15: 531K2025-12-31: 93K2026-01-15: 196K2026-01-30: 120K2026-02-13: 124K2026-02-27: 120K2026-03-13: 153K2026-03-31: 173K2026-04-15: 194K2026-04-30: 731K2026-05-15: 776K2026-05-29: 792K2026-06-15: 768K2026-06-30: 1.8M2026-07-15: 2.0M2026-07-31: 2.6M2026-08-14: 5.5M2026-08-31: 9.3M2026-09-15: 5.5M2026-09-30: 7.2M
the 30 Sep 2026 report24 earlier reportsnormal: 743K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 27 Oct 2026

Tenax Therapeutics had 7.2M shares sold short in the 15 Oct 2026 report, 9.6× the same report last year.

This period
7.2M (the 15 Oct 2026 report)
Normal report (median of 24 earlier)
756K
Typical spread (median absolute deviation)
593K
How far from its usual level
+7.4
Same report last year
754K
History used
3,212 days
2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K2025-12-15: 531K2025-12-31: 93K2026-01-15: 196K2026-01-30: 120K2026-02-13: 124K2026-02-27: 120K2026-03-13: 153K2026-03-31: 173K2026-04-15: 194K2026-04-30: 731K2026-05-15: 776K2026-05-29: 792K2026-06-15: 768K2026-06-30: 1.8M2026-07-15: 2.0M2026-07-31: 2.6M2026-08-14: 5.5M2026-08-31: 9.3M2026-09-15: 5.5M2026-09-30: 7.2M2026-10-15: 7.2M
the 15 Oct 2026 report24 earlier reportsnormal: 756K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Nov 2026

Tenax Therapeutics had 5.8M shares sold short in the 30 Oct 2026 report, 7.6× the same report last year.

This period
5.8M (the 30 Oct 2026 report)
Normal report (median of 24 earlier)
760K
Typical spread (median absolute deviation)
622K
How far from its usual level
+5.5
Same report last year
762K
History used
3,227 days
2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K2025-12-15: 531K2025-12-31: 93K2026-01-15: 196K2026-01-30: 120K2026-02-13: 124K2026-02-27: 120K2026-03-13: 153K2026-03-31: 173K2026-04-15: 194K2026-04-30: 731K2026-05-15: 776K2026-05-29: 792K2026-06-15: 768K2026-06-30: 1.8M2026-07-15: 2.0M2026-07-31: 2.6M2026-08-14: 5.5M2026-08-31: 9.3M2026-09-15: 5.5M2026-09-30: 7.2M2026-10-15: 7.2M2026-10-30: 5.8M
the 30 Oct 2026 report24 earlier reportsnormal: 760K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

6 Dec 2025confirmed

Confirmed across sources Insiders and Short interest and volume

Tenax Therapeutics (TENX): had 758K shares sold short in the 14 Nov 2025 report, 6.3× the same report last year, while it had 4 insiders buy $139K of its shares on the open market within 30 days (4 filings). Two unrelated kinds of activity within 28 days.

  • Short interest and volume: Short interest spike, became public on 13 Nov 2025
  • Short interest and volume: Short interest spike, became public on 26 Nov 2025
  • Insiders: Clustered insider buying, became public on 6 Dec 2025
  • Short interest and volume: Short interest spike, became public on 10 Dec 2025
2024-11-15: 121K2024-11-29: 131K2024-12-13: 205K2024-12-31: 218K2025-01-15: 223K2025-01-31: 217K2025-02-14: 420K2025-02-28: 382K2025-03-14: 373K2025-03-31: 364K2025-04-15: 336K2025-04-30: 308K2025-05-15: 310K2025-05-30: 311K2025-06-13: 311K2025-06-30: 337K2025-07-15: 336K2025-07-31: 335K2025-08-15: 327K2025-08-29: 298K2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K
The 14 Nov 2025 report against the 24 reports before it. this reportearliernormal: 319K
See the evidence (4 changes)

Short interest and volume: Short interest spike became public on 13 Nov 2025

Tenax Therapeutics had 762K shares sold short in the 31 Oct 2025 report, 7.2× the same report last year.

This period
762K (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
311K
Typical spread (median absolute deviation)
58K
How far from its usual level
+5.3
Same report last year
106K
History used
2,863 days
2024-10-31: 106K2024-11-15: 121K2024-11-29: 131K2024-12-13: 205K2024-12-31: 218K2025-01-15: 223K2025-01-31: 217K2025-02-14: 420K2025-02-28: 382K2025-03-14: 373K2025-03-31: 364K2025-04-15: 336K2025-04-30: 308K2025-05-15: 310K2025-05-30: 311K2025-06-13: 311K2025-06-30: 337K2025-07-15: 336K2025-07-31: 335K2025-08-15: 327K2025-08-29: 298K2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K
the 31 Oct 2025 report24 earlier reportsnormal: 311K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Nov 2025

Tenax Therapeutics had 758K shares sold short in the 14 Nov 2025 report, 6.3× the same report last year.

This period
758K (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
319K
Typical spread (median absolute deviation)
50K
How far from its usual level
+5.9
Same report last year
121K
History used
2,877 days
2024-11-15: 121K2024-11-29: 131K2024-12-13: 205K2024-12-31: 218K2025-01-15: 223K2025-01-31: 217K2025-02-14: 420K2025-02-28: 382K2025-03-14: 373K2025-03-31: 364K2025-04-15: 336K2025-04-30: 308K2025-05-15: 310K2025-05-30: 311K2025-06-13: 311K2025-06-30: 337K2025-07-15: 336K2025-07-31: 335K2025-08-15: 327K2025-08-29: 298K2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K
the 14 Nov 2025 report24 earlier reportsnormal: 319K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Insiders: Clustered insider buying became public on 6 Dec 2025

Tenax Therapeutics had 4 insiders buy $139K of its shares on the open market within 30 days (4 filings).

Independent buyers
4
Purchase filings (Form 4, code P)
4
Total bought
$139K
Window
6 Nov 2025 to 6 Dec 2025
  • Almenoff June Sherie (director) bought 1,993 shares of TENX ($14,953)dated 19 Nov 2025, public 20 Nov 2025
  • MCGAULEY THOMAS (Interim CFO) bought 8,000 shares of TENX ($58,180)dated 19 Nov 2025, public 20 Nov 2025
  • Giordano Christopher Thomas (CEO) bought 2,605 shares of TENX ($19,993)dated 20 Nov 2025, public 21 Nov 2025
  • Rich Stuart (Chief Medical Officer) bought 5,000 shares of TENX ($45,630)dated 5 Dec 2025, public 6 Dec 2025

Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

Short interest and volume: Short interest spike became public on 10 Dec 2025

Tenax Therapeutics had 600K shares sold short in the 28 Nov 2025 report, 4.6× the same report last year.

This period
600K (the 28 Nov 2025 report)
Normal report (median of 24 earlier)
331K
Typical spread (median absolute deviation)
47K
How far from its usual level
+3.9
Same report last year
131K
History used
2,891 days
2024-11-29: 131K2024-12-13: 205K2024-12-31: 218K2025-01-15: 223K2025-01-31: 217K2025-02-14: 420K2025-02-28: 382K2025-03-14: 373K2025-03-31: 364K2025-04-15: 336K2025-04-30: 308K2025-05-15: 310K2025-05-30: 311K2025-06-13: 311K2025-06-30: 337K2025-07-15: 336K2025-07-31: 335K2025-08-15: 327K2025-08-29: 298K2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K
the 28 Nov 2025 report24 earlier reportsnormal: 331K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 11 Nov 2026Short interest and volume change

    had 5.8M shares sold short in the 30 Oct 2026 report, 7.6× the same report last year.

    Same report last year: 762K; its normal report is 760K.

    See the evidence
    This period
    5.8M (the 30 Oct 2026 report)
    Normal report (median of 24 earlier)
    760K
    Typical spread (median absolute deviation)
    622K
    How far from its usual level
    +5.5
    Same report last year
    762K
    History used
    3,227 days
    2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K2025-12-15: 531K2025-12-31: 93K2026-01-15: 196K2026-01-30: 120K2026-02-13: 124K2026-02-27: 120K2026-03-13: 153K2026-03-31: 173K2026-04-15: 194K2026-04-30: 731K2026-05-15: 776K2026-05-29: 792K2026-06-15: 768K2026-06-30: 1.8M2026-07-15: 2.0M2026-07-31: 2.6M2026-08-14: 5.5M2026-08-31: 9.3M2026-09-15: 5.5M2026-09-30: 7.2M2026-10-15: 7.2M2026-10-30: 5.8M
    the 30 Oct 2026 report24 earlier reportsnormal: 760K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  2. 27 Oct 2026Short interest and volume change

    had 7.2M shares sold short in the 15 Oct 2026 report, 9.6× the same report last year.

    Same report last year: 754K; its normal report is 756K.

    See the evidence
    This period
    7.2M (the 15 Oct 2026 report)
    Normal report (median of 24 earlier)
    756K
    Typical spread (median absolute deviation)
    593K
    How far from its usual level
    +7.4
    Same report last year
    754K
    History used
    3,212 days
    2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K2025-12-15: 531K2025-12-31: 93K2026-01-15: 196K2026-01-30: 120K2026-02-13: 124K2026-02-27: 120K2026-03-13: 153K2026-03-31: 173K2026-04-15: 194K2026-04-30: 731K2026-05-15: 776K2026-05-29: 792K2026-06-15: 768K2026-06-30: 1.8M2026-07-15: 2.0M2026-07-31: 2.6M2026-08-14: 5.5M2026-08-31: 9.3M2026-09-15: 5.5M2026-09-30: 7.2M2026-10-15: 7.2M
    the 15 Oct 2026 report24 earlier reportsnormal: 756K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  3. 21 Oct 2026Insiders record

    ADAR1 Capital Management, LLC (ten percent owner) and 1 other(s) bought 922,849 shares of TENX ($1.5M)

  4. 10 Oct 2026Short interest and volume change

    had 7.2M shares sold short in the 30 Sep 2026 report, 13× the same report last year.

    Same report last year: 554K; its normal report is 743K.

    See the evidence
    This period
    7.2M (the 30 Sep 2026 report)
    Normal report (median of 24 earlier)
    743K
    Typical spread (median absolute deviation)
    559K
    How far from its usual level
    +7.8
    Same report last year
    554K
    History used
    3,197 days
    2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K2025-12-15: 531K2025-12-31: 93K2026-01-15: 196K2026-01-30: 120K2026-02-13: 124K2026-02-27: 120K2026-03-13: 153K2026-03-31: 173K2026-04-15: 194K2026-04-30: 731K2026-05-15: 776K2026-05-29: 792K2026-06-15: 768K2026-06-30: 1.8M2026-07-15: 2.0M2026-07-31: 2.6M2026-08-14: 5.5M2026-08-31: 9.3M2026-09-15: 5.5M2026-09-30: 7.2M
    the 30 Sep 2026 report24 earlier reportsnormal: 743K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  5. 25 Sep 2026Short interest and volume change

    had 5.5M shares sold short in the 15 Sep 2026 report, 20× the same report last year.

    Same report last year: 275K; its normal report is 666K.

    See the evidence
    This period
    5.5M (the 15 Sep 2026 report)
    Normal report (median of 24 earlier)
    666K
    Typical spread (median absolute deviation)
    470K
    How far from its usual level
    +6.9
    Same report last year
    275K
    History used
    3,182 days
    2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K2025-12-15: 531K2025-12-31: 93K2026-01-15: 196K2026-01-30: 120K2026-02-13: 124K2026-02-27: 120K2026-03-13: 153K2026-03-31: 173K2026-04-15: 194K2026-04-30: 731K2026-05-15: 776K2026-05-29: 792K2026-06-15: 768K2026-06-30: 1.8M2026-07-15: 2.0M2026-07-31: 2.6M2026-08-14: 5.5M2026-08-31: 9.3M2026-09-15: 5.5M
    the 15 Sep 2026 report24 earlier reportsnormal: 666K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  6. 18 Sep 2026Insiders record

    Doogan Declan (director) bought 53,000 shares of TENX ($101,760) (dated 17 Sep 2026)

  7. 16 Sep 2026several at once

    had 9.3M shares sold short in the 31 Aug 2026 report, 31× the same report last year, while it had 3 insiders buy $4.8M of its shares on the open market within 30 days (5 filings). Two unrelated kinds of activity within 91 days.

    See the evidence (8 changes)

    Short interest and volume: Short interest spike became public on 12 Aug 2026

    Tenax Therapeutics had 2.6M shares sold short in the 31 Jul 2026 report, 7.6× the same report last year.

    This period
    2.6M (the 31 Jul 2026 report)
    Normal report (median of 24 earlier)
    433K
    Typical spread (median absolute deviation)
    303K
    How far from its usual level
    +4.7
    Same report last year
    335K
    History used
    3,136 days
    2025-07-31: 335K2025-08-15: 327K2025-08-29: 298K2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K2025-12-15: 531K2025-12-31: 93K2026-01-15: 196K2026-01-30: 120K2026-02-13: 124K2026-02-27: 120K2026-03-13: 153K2026-03-31: 173K2026-04-15: 194K2026-04-30: 731K2026-05-15: 776K2026-05-29: 792K2026-06-15: 768K2026-06-30: 1.8M2026-07-15: 2.0M2026-07-31: 2.6M
    the 31 Jul 2026 report24 earlier reportsnormal: 433K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Aug 2026

    Tenax Therapeutics had 5.5M shares sold short in the 14 Aug 2026 report, 17× the same report last year.

    This period
    5.5M (the 14 Aug 2026 report)
    Normal report (median of 24 earlier)
    542K
    Typical spread (median absolute deviation)
    258K
    How far from its usual level
    +12.9
    Same report last year
    327K
    History used
    3,150 days
    2025-08-15: 327K2025-08-29: 298K2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K2025-12-15: 531K2025-12-31: 93K2026-01-15: 196K2026-01-30: 120K2026-02-13: 124K2026-02-27: 120K2026-03-13: 153K2026-03-31: 173K2026-04-15: 194K2026-04-30: 731K2026-05-15: 776K2026-05-29: 792K2026-06-15: 768K2026-06-30: 1.8M2026-07-15: 2.0M2026-07-31: 2.6M2026-08-14: 5.5M
    the 14 Aug 2026 report24 earlier reportsnormal: 542K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Sep 2026

    Tenax Therapeutics had 9.3M shares sold short in the 31 Aug 2026 report, 31× the same report last year.

    This period
    9.3M (the 31 Aug 2026 report)
    Normal report (median of 24 earlier)
    577K
    Typical spread (median absolute deviation)
    341K
    How far from its usual level
    +17.2
    Same report last year
    298K
    History used
    3,167 days
    2025-08-29: 298K2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K2025-12-15: 531K2025-12-31: 93K2026-01-15: 196K2026-01-30: 120K2026-02-13: 124K2026-02-27: 120K2026-03-13: 153K2026-03-31: 173K2026-04-15: 194K2026-04-30: 731K2026-05-15: 776K2026-05-29: 792K2026-06-15: 768K2026-06-30: 1.8M2026-07-15: 2.0M2026-07-31: 2.6M2026-08-14: 5.5M2026-08-31: 9.3M
    the 31 Aug 2026 report24 earlier reportsnormal: 577K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Insiders: Clustered insider buying became public on 16 Sep 2026

    Tenax Therapeutics had 3 insiders buy $4.8M of its shares on the open market within 30 days (5 filings).

    Independent buyers
    3
    Purchase filings (Form 4, code P)
    5
    Total bought
    $4.8M
    Window
    17 Aug 2026 to 16 Sep 2026
    • Schneeberger Daniel (ten percent owner) and 1 other(s) bought 1,025,867 shares of TENX ($1.8M)dated 24 Aug 2026, public 25 Aug 2026
    • Schneeberger Daniel (ten percent owner) and 1 other(s) bought 770,333 shares of TENX ($1.4M)dated 2 Sep 2026, public 3 Sep 2026
    • ADAR1 Capital Management, LLC (ten percent owner) and 1 other(s) bought 900,000 shares of TENX ($1.6M)dated 8 Sep 2026, public 9 Sep 2026
    • Giordano Christopher Thomas (CEO) bought 10,850 shares of TENX ($20,107)dated 15 Sep 2026, public 16 Sep 2026
    • STAAB THOMAS R II (Chief Financial Officer) bought 5,675 shares of TENX ($11,010)dated 15 Sep 2026, public 16 Sep 2026

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

    Short interest and volume: Short interest spike became public on 25 Sep 2026

    Tenax Therapeutics had 5.5M shares sold short in the 15 Sep 2026 report, 20× the same report last year.

    This period
    5.5M (the 15 Sep 2026 report)
    Normal report (median of 24 earlier)
    666K
    Typical spread (median absolute deviation)
    470K
    How far from its usual level
    +6.9
    Same report last year
    275K
    History used
    3,182 days
    2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K2025-12-15: 531K2025-12-31: 93K2026-01-15: 196K2026-01-30: 120K2026-02-13: 124K2026-02-27: 120K2026-03-13: 153K2026-03-31: 173K2026-04-15: 194K2026-04-30: 731K2026-05-15: 776K2026-05-29: 792K2026-06-15: 768K2026-06-30: 1.8M2026-07-15: 2.0M2026-07-31: 2.6M2026-08-14: 5.5M2026-08-31: 9.3M2026-09-15: 5.5M
    the 15 Sep 2026 report24 earlier reportsnormal: 666K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Oct 2026

    Tenax Therapeutics had 7.2M shares sold short in the 30 Sep 2026 report, 13× the same report last year.

    This period
    7.2M (the 30 Sep 2026 report)
    Normal report (median of 24 earlier)
    743K
    Typical spread (median absolute deviation)
    559K
    How far from its usual level
    +7.8
    Same report last year
    554K
    History used
    3,197 days
    2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K2025-12-15: 531K2025-12-31: 93K2026-01-15: 196K2026-01-30: 120K2026-02-13: 124K2026-02-27: 120K2026-03-13: 153K2026-03-31: 173K2026-04-15: 194K2026-04-30: 731K2026-05-15: 776K2026-05-29: 792K2026-06-15: 768K2026-06-30: 1.8M2026-07-15: 2.0M2026-07-31: 2.6M2026-08-14: 5.5M2026-08-31: 9.3M2026-09-15: 5.5M2026-09-30: 7.2M
    the 30 Sep 2026 report24 earlier reportsnormal: 743K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 27 Oct 2026

    Tenax Therapeutics had 7.2M shares sold short in the 15 Oct 2026 report, 9.6× the same report last year.

    This period
    7.2M (the 15 Oct 2026 report)
    Normal report (median of 24 earlier)
    756K
    Typical spread (median absolute deviation)
    593K
    How far from its usual level
    +7.4
    Same report last year
    754K
    History used
    3,212 days
    2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K2025-12-15: 531K2025-12-31: 93K2026-01-15: 196K2026-01-30: 120K2026-02-13: 124K2026-02-27: 120K2026-03-13: 153K2026-03-31: 173K2026-04-15: 194K2026-04-30: 731K2026-05-15: 776K2026-05-29: 792K2026-06-15: 768K2026-06-30: 1.8M2026-07-15: 2.0M2026-07-31: 2.6M2026-08-14: 5.5M2026-08-31: 9.3M2026-09-15: 5.5M2026-09-30: 7.2M2026-10-15: 7.2M
    the 15 Oct 2026 report24 earlier reportsnormal: 756K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Nov 2026

    Tenax Therapeutics had 5.8M shares sold short in the 30 Oct 2026 report, 7.6× the same report last year.

    This period
    5.8M (the 30 Oct 2026 report)
    Normal report (median of 24 earlier)
    760K
    Typical spread (median absolute deviation)
    622K
    How far from its usual level
    +5.5
    Same report last year
    762K
    History used
    3,227 days
    2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K2025-12-15: 531K2025-12-31: 93K2026-01-15: 196K2026-01-30: 120K2026-02-13: 124K2026-02-27: 120K2026-03-13: 153K2026-03-31: 173K2026-04-15: 194K2026-04-30: 731K2026-05-15: 776K2026-05-29: 792K2026-06-15: 768K2026-06-30: 1.8M2026-07-15: 2.0M2026-07-31: 2.6M2026-08-14: 5.5M2026-08-31: 9.3M2026-09-15: 5.5M2026-09-30: 7.2M2026-10-15: 7.2M2026-10-30: 5.8M
    the 30 Oct 2026 report24 earlier reportsnormal: 760K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  8. 16 Sep 2026Insiders change

    had 3 insiders buy $4.8M of its shares on the open market within 30 days (5 filings).

    Who bought: Giordano Christopher Thomas, Staab Thomas R Ii.

    See the evidence (5 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    5
    Total bought
    $4.8M
    Window
    17 Aug 2026 to 16 Sep 2026
    • Schneeberger Daniel (ten percent owner) and 1 other(s) bought 1,025,867 shares of TENX ($1.8M)dated 24 Aug 2026, public 25 Aug 2026
    • Schneeberger Daniel (ten percent owner) and 1 other(s) bought 770,333 shares of TENX ($1.4M)dated 2 Sep 2026, public 3 Sep 2026
    • ADAR1 Capital Management, LLC (ten percent owner) and 1 other(s) bought 900,000 shares of TENX ($1.6M)dated 8 Sep 2026, public 9 Sep 2026
    • Giordano Christopher Thomas (CEO) bought 10,850 shares of TENX ($20,107)dated 15 Sep 2026, public 16 Sep 2026
    • STAAB THOMAS R II (Chief Financial Officer) bought 5,675 shares of TENX ($11,010)dated 15 Sep 2026, public 16 Sep 2026

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  9. 16 Sep 2026Insiders record

    Giordano Christopher Thomas (CEO) bought 10,850 shares of TENX ($20,107) (dated 15 Sep 2026)

  10. 16 Sep 2026Insiders record

    STAAB THOMAS R II (Chief Financial Officer) bought 5,675 shares of TENX ($11,010) (dated 15 Sep 2026)

  11. 11 Sep 2026Short interest and volume change

    had 9.3M shares sold short in the 31 Aug 2026 report, 31× the same report last year.

    Same report last year: 298K; its normal report is 577K.

    See the evidence
    This period
    9.3M (the 31 Aug 2026 report)
    Normal report (median of 24 earlier)
    577K
    Typical spread (median absolute deviation)
    341K
    How far from its usual level
    +17.2
    Same report last year
    298K
    History used
    3,167 days
    2025-08-29: 298K2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K2025-12-15: 531K2025-12-31: 93K2026-01-15: 196K2026-01-30: 120K2026-02-13: 124K2026-02-27: 120K2026-03-13: 153K2026-03-31: 173K2026-04-15: 194K2026-04-30: 731K2026-05-15: 776K2026-05-29: 792K2026-06-15: 768K2026-06-30: 1.8M2026-07-15: 2.0M2026-07-31: 2.6M2026-08-14: 5.5M2026-08-31: 9.3M
    the 31 Aug 2026 report24 earlier reportsnormal: 577K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 9 Sep 2026Insiders record

    ADAR1 Capital Management, LLC (ten percent owner) and 1 other(s) bought 900,000 shares of TENX ($1.6M) (dated 8 Sep 2026)

  13. 3 Sep 2026Insiders record

    Schneeberger Daniel (ten percent owner) and 1 other(s) bought 770,333 shares of TENX ($1.4M) (dated 2 Sep 2026)

  14. 26 Aug 2026Short interest and volume change

    had 5.5M shares sold short in the 14 Aug 2026 report, 17× the same report last year.

    Same report last year: 327K; its normal report is 542K.

    See the evidence
    This period
    5.5M (the 14 Aug 2026 report)
    Normal report (median of 24 earlier)
    542K
    Typical spread (median absolute deviation)
    258K
    How far from its usual level
    +12.9
    Same report last year
    327K
    History used
    3,150 days
    2025-08-15: 327K2025-08-29: 298K2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K2025-12-15: 531K2025-12-31: 93K2026-01-15: 196K2026-01-30: 120K2026-02-13: 124K2026-02-27: 120K2026-03-13: 153K2026-03-31: 173K2026-04-15: 194K2026-04-30: 731K2026-05-15: 776K2026-05-29: 792K2026-06-15: 768K2026-06-30: 1.8M2026-07-15: 2.0M2026-07-31: 2.6M2026-08-14: 5.5M
    the 14 Aug 2026 report24 earlier reportsnormal: 542K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  15. 25 Aug 2026Insiders record

    Schneeberger Daniel (ten percent owner) and 1 other(s) bought 1,025,867 shares of TENX ($1.8M) (dated 24 Aug 2026)

  16. 12 Aug 2026Short interest and volume change

    had 2.6M shares sold short in the 31 Jul 2026 report, 7.6× the same report last year.

    Same report last year: 335K; its normal report is 433K.

    See the evidence
    This period
    2.6M (the 31 Jul 2026 report)
    Normal report (median of 24 earlier)
    433K
    Typical spread (median absolute deviation)
    303K
    How far from its usual level
    +4.7
    Same report last year
    335K
    History used
    3,136 days
    2025-07-31: 335K2025-08-15: 327K2025-08-29: 298K2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K2025-12-15: 531K2025-12-31: 93K2026-01-15: 196K2026-01-30: 120K2026-02-13: 124K2026-02-27: 120K2026-03-13: 153K2026-03-31: 173K2026-04-15: 194K2026-04-30: 731K2026-05-15: 776K2026-05-29: 792K2026-06-15: 768K2026-06-30: 1.8M2026-07-15: 2.0M2026-07-31: 2.6M
    the 31 Jul 2026 report24 earlier reportsnormal: 433K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 29 Jun 2026Filings record

    Director or officer change

  18. 15 May 2026Institutional holdings change

    saw 30 13F filers open a new position in the quarter ended 31 Mar 2026, 7.5× the same quarter last year.

    Same quarter last year: 4; its normal quarter is 4.5.

    See the evidence
    This period
    30 (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    4.5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +8.5
    Same quarter last year
    4
    History used
    4,200 days
    2024-03-31: 32024-06-30: 42024-09-30: 122024-12-31: 52025-03-31: 42025-06-30: 22025-09-30: 112025-12-31: 172026-03-31: 30
    the quarter ended 31 Mar 20268 earlier quartersnormal: 4.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  19. 22 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  20. 22 Apr 2026Filings record

    Director or officer change

  21. 9 Jan 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  22. 9 Jan 2026Filings record

    Director or officer change

  23. 11 Dec 2025Insiders record

    Rich Stuart (Chief Medical Officer) bought 5,000 shares of TENX ($50,800) (dated 10 Dec 2025)

  24. 10 Dec 2025Short interest and volume change

    had 600K shares sold short in the 28 Nov 2025 report, 4.6× the same report last year.

    Same report last year: 131K; its normal report is 331K.

    See the evidence
    This period
    600K (the 28 Nov 2025 report)
    Normal report (median of 24 earlier)
    331K
    Typical spread (median absolute deviation)
    47K
    How far from its usual level
    +3.9
    Same report last year
    131K
    History used
    2,891 days
    2024-11-29: 131K2024-12-13: 205K2024-12-31: 218K2025-01-15: 223K2025-01-31: 217K2025-02-14: 420K2025-02-28: 382K2025-03-14: 373K2025-03-31: 364K2025-04-15: 336K2025-04-30: 308K2025-05-15: 310K2025-05-30: 311K2025-06-13: 311K2025-06-30: 337K2025-07-15: 336K2025-07-31: 335K2025-08-15: 327K2025-08-29: 298K2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K
    the 28 Nov 2025 report24 earlier reportsnormal: 331K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 6 Dec 2025several at once

    had 758K shares sold short in the 14 Nov 2025 report, 6.3× the same report last year, while it had 4 insiders buy $139K of its shares on the open market within 30 days (4 filings). Two unrelated kinds of activity within 28 days.

    See the evidence (4 changes)

    Short interest and volume: Short interest spike became public on 13 Nov 2025

    Tenax Therapeutics had 762K shares sold short in the 31 Oct 2025 report, 7.2× the same report last year.

    This period
    762K (the 31 Oct 2025 report)
    Normal report (median of 24 earlier)
    311K
    Typical spread (median absolute deviation)
    58K
    How far from its usual level
    +5.3
    Same report last year
    106K
    History used
    2,863 days
    2024-10-31: 106K2024-11-15: 121K2024-11-29: 131K2024-12-13: 205K2024-12-31: 218K2025-01-15: 223K2025-01-31: 217K2025-02-14: 420K2025-02-28: 382K2025-03-14: 373K2025-03-31: 364K2025-04-15: 336K2025-04-30: 308K2025-05-15: 310K2025-05-30: 311K2025-06-13: 311K2025-06-30: 337K2025-07-15: 336K2025-07-31: 335K2025-08-15: 327K2025-08-29: 298K2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K
    the 31 Oct 2025 report24 earlier reportsnormal: 311K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Nov 2025

    Tenax Therapeutics had 758K shares sold short in the 14 Nov 2025 report, 6.3× the same report last year.

    This period
    758K (the 14 Nov 2025 report)
    Normal report (median of 24 earlier)
    319K
    Typical spread (median absolute deviation)
    50K
    How far from its usual level
    +5.9
    Same report last year
    121K
    History used
    2,877 days
    2024-11-15: 121K2024-11-29: 131K2024-12-13: 205K2024-12-31: 218K2025-01-15: 223K2025-01-31: 217K2025-02-14: 420K2025-02-28: 382K2025-03-14: 373K2025-03-31: 364K2025-04-15: 336K2025-04-30: 308K2025-05-15: 310K2025-05-30: 311K2025-06-13: 311K2025-06-30: 337K2025-07-15: 336K2025-07-31: 335K2025-08-15: 327K2025-08-29: 298K2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K
    the 14 Nov 2025 report24 earlier reportsnormal: 319K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Insiders: Clustered insider buying became public on 6 Dec 2025

    Tenax Therapeutics had 4 insiders buy $139K of its shares on the open market within 30 days (4 filings).

    Independent buyers
    4
    Purchase filings (Form 4, code P)
    4
    Total bought
    $139K
    Window
    6 Nov 2025 to 6 Dec 2025
    • Almenoff June Sherie (director) bought 1,993 shares of TENX ($14,953)dated 19 Nov 2025, public 20 Nov 2025
    • MCGAULEY THOMAS (Interim CFO) bought 8,000 shares of TENX ($58,180)dated 19 Nov 2025, public 20 Nov 2025
    • Giordano Christopher Thomas (CEO) bought 2,605 shares of TENX ($19,993)dated 20 Nov 2025, public 21 Nov 2025
    • Rich Stuart (Chief Medical Officer) bought 5,000 shares of TENX ($45,630)dated 5 Dec 2025, public 6 Dec 2025

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

    Short interest and volume: Short interest spike became public on 10 Dec 2025

    Tenax Therapeutics had 600K shares sold short in the 28 Nov 2025 report, 4.6× the same report last year.

    This period
    600K (the 28 Nov 2025 report)
    Normal report (median of 24 earlier)
    331K
    Typical spread (median absolute deviation)
    47K
    How far from its usual level
    +3.9
    Same report last year
    131K
    History used
    2,891 days
    2024-11-29: 131K2024-12-13: 205K2024-12-31: 218K2025-01-15: 223K2025-01-31: 217K2025-02-14: 420K2025-02-28: 382K2025-03-14: 373K2025-03-31: 364K2025-04-15: 336K2025-04-30: 308K2025-05-15: 310K2025-05-30: 311K2025-06-13: 311K2025-06-30: 337K2025-07-15: 336K2025-07-31: 335K2025-08-15: 327K2025-08-29: 298K2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K2025-11-28: 600K
    the 28 Nov 2025 report24 earlier reportsnormal: 331K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  26. 6 Dec 2025Insiders change

    had 4 insiders buy $139K of its shares on the open market within 30 days (4 filings).

    Who bought: Almenoff June Sherie, Mcgauley Thomas, Giordano Christopher Thomas, Rich Stuart.

    See the evidence (4 source records)
    Independent buyers
    4
    Purchase filings (Form 4, code P)
    4
    Total bought
    $139K
    Window
    6 Nov 2025 to 6 Dec 2025
    • Almenoff June Sherie (director) bought 1,993 shares of TENX ($14,953)dated 19 Nov 2025, public 20 Nov 2025
    • MCGAULEY THOMAS (Interim CFO) bought 8,000 shares of TENX ($58,180)dated 19 Nov 2025, public 20 Nov 2025
    • Giordano Christopher Thomas (CEO) bought 2,605 shares of TENX ($19,993)dated 20 Nov 2025, public 21 Nov 2025
    • Rich Stuart (Chief Medical Officer) bought 5,000 shares of TENX ($45,630)dated 5 Dec 2025, public 6 Dec 2025

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  27. 6 Dec 2025Insiders record

    Rich Stuart (Chief Medical Officer) bought 5,000 shares of TENX ($45,630) (dated 5 Dec 2025)

  28. 26 Nov 2025Short interest and volume change

    had 758K shares sold short in the 14 Nov 2025 report, 6.3× the same report last year.

    Same report last year: 121K; its normal report is 319K.

    See the evidence
    This period
    758K (the 14 Nov 2025 report)
    Normal report (median of 24 earlier)
    319K
    Typical spread (median absolute deviation)
    50K
    How far from its usual level
    +5.9
    Same report last year
    121K
    History used
    2,877 days
    2024-11-15: 121K2024-11-29: 131K2024-12-13: 205K2024-12-31: 218K2025-01-15: 223K2025-01-31: 217K2025-02-14: 420K2025-02-28: 382K2025-03-14: 373K2025-03-31: 364K2025-04-15: 336K2025-04-30: 308K2025-05-15: 310K2025-05-30: 311K2025-06-13: 311K2025-06-30: 337K2025-07-15: 336K2025-07-31: 335K2025-08-15: 327K2025-08-29: 298K2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K2025-11-14: 758K
    the 14 Nov 2025 report24 earlier reportsnormal: 319K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 21 Nov 2025Insiders record

    Giordano Christopher Thomas (CEO) bought 2,605 shares of TENX ($19,993) (dated 20 Nov 2025)

  30. 21 Nov 2025Insiders record

    Almenoff June Sherie (director) bought 1,993 shares of TENX ($14,953) [amended] (dated 20 Nov 2025)

  31. 20 Nov 2025Insiders record

    Almenoff June Sherie (director) bought 1,993 shares of TENX ($14,953) (dated 19 Nov 2025)

  32. 20 Nov 2025Insiders record

    MCGAULEY THOMAS (Interim CFO) bought 8,000 shares of TENX ($58,180) (dated 19 Nov 2025)

  33. 13 Nov 2025Short interest and volume change

    had 762K shares sold short in the 31 Oct 2025 report, 7.2× the same report last year.

    Same report last year: 106K; its normal report is 311K.

    See the evidence
    This period
    762K (the 31 Oct 2025 report)
    Normal report (median of 24 earlier)
    311K
    Typical spread (median absolute deviation)
    58K
    How far from its usual level
    +5.3
    Same report last year
    106K
    History used
    2,863 days
    2024-10-31: 106K2024-11-15: 121K2024-11-29: 131K2024-12-13: 205K2024-12-31: 218K2025-01-15: 223K2025-01-31: 217K2025-02-14: 420K2025-02-28: 382K2025-03-14: 373K2025-03-31: 364K2025-04-15: 336K2025-04-30: 308K2025-05-15: 310K2025-05-30: 311K2025-06-13: 311K2025-06-30: 337K2025-07-15: 336K2025-07-31: 335K2025-08-15: 327K2025-08-29: 298K2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K2025-10-31: 762K
    the 31 Oct 2025 report24 earlier reportsnormal: 311K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 25 Oct 2025Short interest and volume change

    had 754K shares sold short in the 15 Oct 2025 report, 36× the same report last year.

    Same report last year: 21K; its normal report is 310K.

    See the evidence
    This period
    754K (the 15 Oct 2025 report)
    Normal report (median of 24 earlier)
    310K
    Typical spread (median absolute deviation)
    58K
    How far from its usual level
    +5.1
    Same report last year
    21K
    History used
    2,847 days
    2024-10-15: 21K2024-10-31: 106K2024-11-15: 121K2024-11-29: 131K2024-12-13: 205K2024-12-31: 218K2025-01-15: 223K2025-01-31: 217K2025-02-14: 420K2025-02-28: 382K2025-03-14: 373K2025-03-31: 364K2025-04-15: 336K2025-04-30: 308K2025-05-15: 310K2025-05-30: 311K2025-06-13: 311K2025-06-30: 337K2025-07-15: 336K2025-07-31: 335K2025-08-15: 327K2025-08-29: 298K2025-09-15: 275K2025-09-30: 554K2025-10-15: 754K
    the 15 Oct 2025 report24 earlier reportsnormal: 310K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  35. 4 Dec 2024Filings record

    Director or officer change

  36. 30 Oct 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  37. 30 Oct 2024Filings record

    Director or officer change

  38. 23 Aug 2024Filings record

    Private placement of securities (Form D)

  39. 9 Aug 2024Insiders record

    PROEHL GERALD T (director) bought 1,666 shares of TENX (dated 8 Aug 2024)

  40. 9 Aug 2024Insiders record

    Davidson Michael H. (director) bought 2,500 shares of TENX (dated 8 Aug 2024)

Showing the newest 40 of 113 entries; narrow the window or the kind of data to see older ones.

Not listed: 115 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000034956
Ticker
TENX
Domain
tenaxthera.com
Hq location
NC|CHAPEL HILL|27517 (1 unverified)
Name
OXYGEN BIOTHERAPEUTICS, INC., SYNTHETIC BLOOD INTERNATIONAL INC, Tenax Therapeutics, Inc.
Uei
N5YWD27TA8U6
  • SEC Form 13F institutional holdings441 data points30 Sep 2014 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)160 records14 Mar 2016 to 5 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)911 data points25 May 1967 to 31 Oct 2026
  • SEC Form 4 insider transactions25 records, 84 data points19 Feb 2016 to 21 Oct 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4174 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards1 record, 57 data points10 Sep 2008 to 19 Sep 2016